Predictors of metabolic response in propensity-matched lymphoma patients on interim 18F-fluorodeoxyglucose positron-emission tomography/computed tomography using standardized imaging and reporting protocol: Do we really have one? by Fatima, Nosheen et al.
eCommons@AKU
Department of Radiology Medical College, Pakistan
April 2019
Predictors of metabolic response in propensity-
matched lymphoma patients on interim 18F-
fluorodeoxyglucose positron-emission
tomography/computed tomography using
standardized imaging and reporting protocol: Do
we really have one?
Nosheen Fatima
Aga Khan University, nosheen.fatima@aku.edu
Maseeh uz Zaman
Aga Khan University, maseeh.uzzaman@aku.edu
Areeba Zaman
Aga Khan University, areeba.zaman@aku.edu
Unaiza Zaman
Aga Khan University, Unaiza.zaman@aku.edu
Rabia Tehseen
Aga Khan University, rabia.tahseen@aku.edu
Recommended Citation
Fatima, N., uz Zaman, M., Zaman, A., Zaman, U., Tehseen, R., Zaman, S. (2019). Predictors of metabolic response in propensity-
matched lymphoma patients on interim 18F-fluorodeoxyglucose positron-emission tomography/computed tomography using
standardized imaging and reporting protocol: Do we really have one?. World Journal of Nuclear Medicine, 18(2), 154-159.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_radiol/342
See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_radiol
Authors
Nosheen Fatima, Maseeh uz Zaman, Areeba Zaman, Unaiza Zaman, Rabia Tehseen, and Sidra Zaman
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_radiol/342
6/21/2019 Predictors of metabolic response in propensity-matched lymphoma patients on interim 18F-fluorodeoxyglucose positron-emission tomogr…
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476257/?report=printable 1/14




Predictors of metabolic response in propensity-matched lymphoma
patients on interim F-fluorodeoxyglucose positron-emission
tomography/computed tomography using standardized imaging and
reporting protocol: Do we really have one?
Nosheen Fatima, Maseeh Uz Zaman, Areeba Zaman,  Unaiza Zaman,  Rabia Tahseen,  and Sidra Zaman
Department of Radiology, The Aga Khan University Hospital, Karachi, Pakistan
Dow University of Health Sciences, Karachi, Pakistan
Department of Medicine, Dr. Ruth Pfau Hospital, Dow University of Health Sciences, Karachi, Pakistan
Department of Radiation Oncology, The Aga Khan University Hospital, Karachi, Pakistan
Address for correspondence: Prof. Maseeh Uz Zaman, Department of Radiology, The Aga Khan University
Hospital Karachi, Pakistan. E-mail: maseeh.uzzaman@aku.edu
Copyright : © 2019 World Journal of Nuclear Medicine
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-
commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Abstract
The purpose of this prospective study was to determine metabolic response predictor(s) in propensity-
matched patients having lymphomas who had baseline and interim fluorodeoxyglucose (FDG) positron-
emission tomography/computed tomography (PET/CT) using strict standardized imaging and reporting
protocols. This prospective study was conducted at PET/CT section of a JCI-accredited healthcare facility
from April 2017 to February 2018. Patients with baseline and interim FDG PET/CT scans using
standardized protocol were selected. Interim scans were performed not earlier than 2  or later than 4
chemotherapy. During the study period, 97 of 112 consecutive patients with lymphomas (Hodgkin-HL:
32/97 and Non-Hodgkin-NHL: 65/97) were included in the study. Mean age of cohort was 45 ± 19 years
(71% male and 29% female) having a mean body mass index (BMI) of 25.57 ± 5.54 Kg/m  having Stage I
(21%), Stage II (18%), Stage III (16%), and Stage IV (45%) disease. Bulky disease was found in 14% and
FDG-avid marrow deposits in 33%. Standardized PET/CT imaging protocol as per EANM guidelines
was strictly adopted for baseline and interim studies. %Δ changes in fasting blood sugar, FDG dose,
uptake time, and liver SUV mean were 3.96%, 2.83%, 2.49%, and 12.15%, respectively. Based on
Deauville's scoring, cohort was divided into responders having Score 1–3 (49/97) and nonresponders
having Score 4–5 (48/97). The demographic analysis found no significant difference between responders
and nonresponders for age, gender, BMI, staging, bulky disease or marrow involvement, and study
protocol. No significant coefficient or odd ratios were found on multivariate analysis for age, gender,
maximum standardized uptake value (SUV ), size, BMI, NHL, and advance disease (Stage III and IV)
in both groups (χ : 5.12; receiver operating characteristic [95% confidence interval]: 0.616 [0.51–0.713]; P
=0.528). Among responders, baseline SUV  and tumor size had a direct correlation with a metabolic
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response on iPET, more pronounced in NHL than HL groups (SUV : 13.4 vs. 19.5 and size: 52 vs. 87
mm; P < 0.0001). We conclude that no significant predictor was found for response in propensity-matched
patients with lymphomas (both HL and NHL) who had baseline and interim PET/CTs acquired with a
standardized protocol. However, NHL responders were found to have higher baseline median SUV  and
larger lesion size as compared to HL responders. Although, these data are not in concordance with
published findings but need to be validated with larger studies using standardized imaging and reporting
protocols in propensity-matched patients with lymphomas.
Keywords: Interim positron-emission tomography/computed tomography, lymphoma, metabolic response,
predictors, standardization
INTRODUCTION
In the Western world, lymphoma is the 6  most common malignancy which accounts for 4.8% of all
malignancies.[1] Lymphomas are treated with chemotherapy, immune-chemotherapy, or radiation therapy,
either as monotherapy or as combined modality treatment. In current practice, F-FlouroDeoxyglucose
positron-emission tomography/computed tomography ( FDG PET/CT) is considered as the standard of
care due to its high diagnostic accuracy in staging and response evaluation at the end of treatment (ePET).
[2] Interim PET/CT (iPET) performed during chemotherapy is being widely investigated in Hodgkin's
lymphoma (HL), diffuse large B-Cell lymphomas, and other subsets of non-HL (NHL) for response-
adapted therapy.[3] However, results are quite variable as a negative iPET has high negative predictive
value (>80%) but a positive iPET has significantly low positive predictive value (around 15%) for
progression-free survival (PFS).[3] This is because iPET cannot discriminate between the presence of
residual viable neoplastic tissue and a nonspecific inflammatory host response.[3,4] This heterogeneity is
caused by adjustable and nonmodifiable factors seen in patient population of published studies. Adjustable
factors include age and gender (significantly different age groups with gender predominance),
nonstandardized imaging protocols, and interpretation criteria used in different studies. Nonmodifiable
factors include tumor behavior and presence of microenvironment cells such as CD8+ tumor-infiltrating
lymphocytes and PD1-positive lymphocytes.[5] Hence, it is imperative to conduct studies on patients’
population with minimal impact of above-mentioned adjustable factors.
The purpose of this study was to determine metabolic response predictor(s) in propensity-matched patients
having lymphomas who had baseline and interim FDG PET/CT using a standardized imaging and
interpretation protocols.
MATERIAL AND METHODS
This prospective study was conducted at PET/CT Section of Department of Radiology, Aga Khan
University Hospital Karachi, Pakistan from July 2017 to February 2018. We included patients with biopsy-
proven lymphomas which were referred for FDG PET/CT studies at baseline and midtreatment scan
performed not earlier than 2  or later than 4  chemotherapy (iPET) for response evaluation. We strictly
followed a standardized protocol for FDG PET/CT as per European Association of Nuclear Medicine
(EANM) guidelines for both studies.[6] Response evaluation was assessed on visual assessment using
Deauville's 5-point scoring system[7] and patients with Score 1–3 were considered as responders
(complete metabolic response) while those with Scores 4 and 5 as nonresponders (partial metabolic
response).












6/21/2019 Predictors of metabolic response in propensity-matched lymphoma patients on interim 18F-fluorodeoxyglucose positron-emission tomogr…
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476257/?report=printable 3/14
FDG PET/CT was performed as per the institutional protocol adopted from EANM guidelines.[6] All
patients had 4–6 h fasting (only plain water was allowed) and a fasting blood sugar <200 mg% before
receiving an intravenous FDG dose of 3 MBq/Kg in the uptake room. During uptake period, (55–75
min) patients were requested to lie comfortably and allowed to take about 500–1000 ml of plain water.
Bladder was emptied before call the patient for PET/CT imaging suite equipped with Celesteion, Toshiba,
Japan. A low-dose CT examination (midbrain to midthigh) from head to toe followed by acquisition of
PET imaging using 3 min/bed position from toe to head in all patients. Follow-up scans were performed
with the same protocols, keeping FDG dose, uptake time, and hepatic SUV mean of baseline and follow-
up studies within ±10%, ±15%, and 20% minutes, respectively, as per published recommendations.[8]
Nodal mass ≥10 cm was considered as a bulky disease and splenomegaly when ≥13 cm.[9] SUV  were
measured over the hottest tumor deposits in both scans and % change in the highest SUV  of baseline
and iPET studies (%△SUV ) were also measured. Similarly, % change in size of the largest lesion
(%△ size) in baseline and iPET scans were also measured.
Statistical analysis
Comparisons between patient groups were performed using Student's t-test for continuous variables and
the Chi-square test for categorical variables. Continuous variables were described by mean ± standard
deviation. Multiple regression analysis was performed to calculate the area under the curve and odd ratios
for age, gender, body mass index (BMI), baseline SUV , bulky disease, and baseline lesion size in
lymphoma responders. Kaplan–Meier cumulative response for HL and NHL responders was performed,
and curves were compared using the log-rank test. The median response for age, BMI, baseline SUV ,
and baseline largest lesion size was expressed with a corresponding 95% of confidence interval [CI].
Statistical significance was defined as a value of P < 0.05. Commercially, available packages Microsoft
excel 2010, Medcalc,  and statistical package for social sciences (SPSS 19 (IBM Company, SPSS, Inc,
USA) ) were used.
RESULTS
During the study period, 97 of 112 consecutive patients (15 patients who did not have iPET were
excluded) with lymphomas. Thirty-two patients (32/97) had HL while 65/97 had NHL. Mean age of total
cohort was 45 ± 19 years (71% male and 29% female) having a mean BMI of 25.57 ± 5.54 Kg/m  [Table 1
]. Patients were categorized to have Stage I (21%), Stage II (18%), Stage III (16%), and Stage IV (45%)
disease [Table 2]. Bulky disease was found in 14%, splenic involvement in 30%, hepatic in 09%,
extralymphatic in 37%, and 33% had FDG-avid marrow deposits [Table 2]. Pulmonary nodules (both
FDG avid and nonavid) were seen in 29% while pleural effusion and ascites were seen in 9% and 4%,
respectively [Table 2]. %Δ changes in fasting blood sugar, FDG dose, uptake time, and liver SUVmean
were 3.96%, 2.83%, 2.49%, and 12.15%, respectively [Table 1]. Based on Deauville's scoring, cohort was
divided into responders having Score 1–3 (49/97); [Figure 1] and nonresponders having Score 4 and 5
(48/97; [Figure 2 and Table 1]. Demographic analysis found no significant difference between responders
and nonresponders for age, gender, BMI, staging, the presence of bulky disease or marrow involvement,
and study protocol (baseline and iPET) [Tables 1 and 2]. No significant coefficient or odd ratios were
found on multivariate analysis for age, gender, SUV , size, BMI, NHL, and advance disease (stage III
and IV) in both groups (χ : 5.12; receiver operating characteristic [95% CI]: 0.616 (0.51–0.713); P =0.528)
[Table 3]. Among the responders, 18/49 had HL and 31/49 had NHL. HL responders were found to be
significantly younger with significant fall in BMI on iPET as compared to NHL responders. Rest of the
variables was found to be nonsignificant Table 4. Among the responders, median SUV  and size were
significantly lower in HL as compared to NHL (SUV : 13.4 vs. 19.5 and size: 52 vs. 87 mm; P <
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DISCUSSION
FDG PET/CT has revolutionized the management of lymphomas and considered as gold standard for
accurate staging and response evaluation at the end of treatment.[10] However, the role of interim FDG
PET/CT (iPET) in response adaptation in lymphomas (especially in NHL) is under evaluation due to
variable results observed in various trials.[9] The basic reason is high false-positive rate ranging from 57%
[11] to 94%[12] due to FDG uptake by posttherapy inflammatory tissue rather than viable tumor.[13]
Other possible reasons for variable results are heterogeneity in patients’ population (age and gender
predominance), nonstandardized imaging, and interpretation criteria used in different studies. In the
present study, we studied the factors predicting the metabolic response on iPET scan.
In this study, age was not found to have significant relation in responders and nonresponders which is in
contradiction to published facts that age is considered as a negative predictor of response.[14] BMI is
considered as a better predictor of response and overall survival (OS) in patients with lymphoma.[15] Our
data did not show any impact of BMI in responders and nonresponders. This is in concordance with
another published study which also failed to show the impact of BMI on metabolic response.[16] Response
rate (Deauville score 1–3 on iPET) was >50% in HL while <50% in NHL, but these were not statistically
significant which could be attributed to small sample size. However, this response rate is almost similar to
a recently published study having a response rate of 53%[12] but significantly lower than another study
having a response rate as high as 72%.[11] Importantly, SUV  and size of the largest lesion on baseline
PET/CT did not show any significant difference between responders and nonresponders on iPET. Our
findings are in concordance with another published study which did not find any significant correlation of
baseline SUV  with response on iPET.[17] Univariate and multivariate analyses also failed to show any
significant impact of age, gender, BMI, baseline SUV  and lesion size, NHL, and advance disease on
the metabolic response on iPET. These observations are surprising as most of the published studies did
find the impact of these factors on PFS. However, we have investigated the impact of these factors on the
metabolic response on iPET and not PFS or OS as data are being collected in studied cohort until writing
this manuscript. We feel that large sample size studies with propensity-matched patients having FDG
PET/CTs with standardized imaging and reporting protocols are deemed necessary to further explore this
observation.
We did not observe any significant difference of staging, extranodal involvement, bulky disease, and
marrow involvement between responders and nonresponders. These observations are in contradiction to
published findings revealing the poor impact of bulky disease, staging, and extranodal involvement on
PFS.[14] HL responders were found to be significantly younger with a higher decline in BMI as compared
to NHL responders. This could be secondary to wider range of BMI at baseline in HL patients. This was
also confirmed by no statistically significant difference on cumulative response by median BMI in both
HL and NHL groups (P = 0.546).
Another important observation in our study is that baseline SUV  and tumor size among total cohort
(more pronounced in NHL than HL) had a direct correlation with a metabolic response on iPET. This is in
contradiction to the study by Mikhaeel et al.,[18] revealing negative impact of SUV  and metabolically
active tumor burden on PFS. However, in current study, we have studied the impact of metabolic response
on iPET and we need longer follow-up to validate these findings for PFS.
Our study has some limitations which need to be addressed in the future studies. First, the sample size is
small which was due to strict inclusion criteria. We did not include those patients who had baseline
PET/CT performed outside for the sake of maintaining standardization. Second, we did not validate
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NHL responders to see the response in early and advanced disease as it would further attenuate the sample
size. Fourth, end point of our study is metabolic response on iPET rather than PFS which needs follow-up
which is currently underway.
CONCLUSION
We conclude that no significant predictor was found for response in propensity-matched patients with
lymphomas (both HL and NHL) who had baseline and interim PET/CT acquired with a standardized
protocol. However, NHL responders were found to have higher baseline median SUV  and larger lesion
size as compared to HL responders. Although, these data are not in concordance with published findings
but need to be validated with larger studies using standardized imaging and reporting protocols in
propensity-matched patients with lymphomas.
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Table 1
Patients’ demographics in Hodgkin and Non-Hodgkin lymphomas labeled as a responder and
nonresponder on interim fluorodeoxyglucose positron-emission tomography/computed
tomography study


















37:11 (77%:23%) 1.676 0.195
BMI (kg/m ) (mean±SD) 25.57±5.54 26.18±5.58 24.95±5.48 −1.095 0.276
%Δ BMI (mean±SD) 0.44%±7.44% 0.81%±7.09% 0.07%±7.83% −0.488 0.627
%Δ FBS (mean±SD) 3.96%±23.75% 6.83%±28.76% 1.91%±21.42% −0.954 0.343
%Δ FDG dose (mean±SD) 2.83%±27.61% 0.04%±34.11% 5.76%±18.73% 1.021 0.310
%Δ Uptake period (mean±SD) 2.49%±20.55% 1.38%±18.78% 3.63%±22.35% 0.537 0.592
%Δ Mean hepatic uptake
(mean±SD)
12.15%±34.60% 16.52%±34.94% 7.95±34.10 −1.222 0.225
%Δ CTDI (mean±SD) 9.77%±24.32% 10.90%±26.18% 8.61±22.47 −0.462 0.645
%Δ DLP (mean±SD) 8.59%±23.24% 7.51%±23.54% 9.68%±23.14% 0.458 0.648
Hodgkin lymphoma (%) 32 (33) 18 (56) 14 (44) 1.382 0.239
Non-Hodgkin lymphoma (%) 65 (67) 31 (48) 34 (52) 0.154 0.695
Highest SUV, (mean±SD) 13.7±8.3 14.0±8.25 13.29±8.49 −0.418 0.677
Largest lesion (mm),
(mean±SD)
58±47 62±49 55±46 −0.725 0.470
%Δ in highest SUV ,
(mean±SD)
58%±41% 81%±21% 34%±41% −7.127 <0.0001*
%Δ lesion size, Mean±SD 58%±42% 68%±24% 47%±53% −2.522 0.0133*
Open in a separate window
*P<0.05. BMI: Body mass index; SD: Standard deviation; FBS: Fasting blood sugar; CTDI: Computed tomography


















Stage I 20 (21) 11 (22) 9 (19) 0.132 0.716
Stage II 17 (18) 8 (16) 9 (19) 0.150 0.699
Stage III 16 (16) 8 (16) 8 (17) 0.017 0.895
Stage IV 44 (45) 22 (45) 22 (45) 0.000 1.000
Spleen involvement 29 (30) 13 (27) 16 (33) 0.412 0.521
Liver involvement 9 (9) 3 (6) 6 (12) 1.058 0.304
Bulky disease ≥100 mm 14 (14) 7 (14) 7 (15) 0.019 0.889
Marrow involvement 32 (33) 16 (33) 16 (33) 0.000 1.000
Extra lymphoid organ
involvement
36 (37) 17 (35) 19 (40) 0.256 0.613
Lung nodules 28 (29) 15 (31) 13 (27) 0.186 0.666
Pleural effusion 9 (09) 5 (10) 4 (08) 0.117 0.732
Ascites 4 (04) 2 (04) 2 (04) 0.000 1.000
Incidental findings 25 (26) 10 (20) 15 (31) 1.531 0.216
*P<0.05
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Figure 1
Six-year-old male with a known case of classical Hodgkin's lymphoma, fluorodeoxyglucose positron-emission
tomography/computed tomography revealed Stage IV disease on baseline and complete metabolic response (score 01 on
Deauville 5PS) on interim scan after receiving 4  cycle of chemotherapy
18
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Figure 2
Twenty-three-year-old male with a known case of classical Hodgkin's lymphoma, fluorodeoxyglucose positron-
emission tomography/computed tomography revealed Stage IV disease on baseline and partial metabolic response (score
05 on Deauville 5PS) on interim scan after receiving 2  cycle of chemotherapy
18
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Table 3
Lymphoma response on interim fluorodeoxyglucose positron-emission tomography/computed
tomography in correlation with age, baseline maximum standardized uptake value, baseline largest
lesion, and baseline body mass index
Lymphoma response versus variables Logistic
regression χ
Area under the ROC Curve
(95% CI)
P
Age + gender + SUV  + size+ BMI + NHL +
advanced disease
5.122 0.616 (0.512-0.713) 0.528
Lymphoma response versus variables Coefficient (SE) OR (95% CI) P
Age (years) −0.015 (0.014) 0.985 (0.958-1.012) 0.270
Male gender −0.504 (0.472) 0.604 (0.239-1.523) 0.286
Baseline SUV 0.008 (0.028) 1.008 (0.954-1.065) 0.781
Baseline largest lesion (mm) 0.008 (0.05) 1.003 (0.993-1.013) 0.590
Baseline BMI (kg/m ) 0.054 (0.040) 1.056 (0.975-1.144) 0.183
NHL −0.135 (0.543) 0.873 (0.301-2.532) 0.803
Advance disease (Stage III, IV and Bulky disease) 0.064 (0.048) 1.066 (0.413-2.751) 0.895
*P<0.05. SUV : Maximum standardized uptake value; BMI: Body mass index; CI: Confidence interval; SE:
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Table 4
Demographic comparisons in Hodgkin and non-Hodgkin lymphomas labeled as responders on
interim fluorodeoxyglucose positron-emission tomography/computed tomography study
Variables Responders
(n=49)
HL (n=18) NHL (n=31) Test
values
P







Gender (male:female) 32:17 (65%:35%) 11:07 (61%:39%) 21:10
(68%:32%)
1.676 0.195
BMI (kg/m ), (mean±SD) 26.18%±5.58% 24.38%±7.33% 26.15%±4.35% 1.064 0.293
%Δ BMI, (mean±SD) 0.81%±7.09% −3.42%±5.67% 1.02%±7.69% 2.076 0.043*
%Δ FBS, (mean±SD) 6.83%±28.76% −0.54%±15.00% 5.64%±26.34% −0.911 0.367
%Δ FDG dose, (mean±SD) −1.00%±15.00% 1.13%±21.0% 3.67%±30.53% 0.312 0.756
%Δ Uptake period, (mean±SD) 1.38%±18.78% 0.62%±20.93% −4.03%±20.34% −0.763 0.449
%Δ Mean hepatic uptake,
(mean±SD)
16.52±%34.94% −9.25%±23.80% −3.58±38.93 0.585 0.561
%Δ CTDI, (mean±SD) 10.90%±26.18% −12.5%±24.28% −8.41±24.41 0.567 0.574
%Δ DLP (mean±SD) 7.51%±23.54% −10.56%
±24.79%
−7.62%±22.58% 0.424 0.674
Highest SUV , mean±SD
(range)





Largest lesion (mm), mean±SD
(range)
62±49 (12-266) 45±28 (12-95) 53±46 (14-266) 0.668 0.507


















*P<0.05. SD: Standard deviation; BMI: Body mass index; FBS: Fasting blood sugar; CTDI: Computed tomography
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Figure 3
Open in a separate window
Kaplan–Meier plot for cumulative response on first interim positron-emission tomography/computed tomography in
Hodgkin and non-Hodgkin lymphomas against the highest median baseline maximum standardized uptake value. HL =
Hodgkin lymphoma, NHL = Non-Hodgkin lymphoma
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Figure 4
Open in a separate window
Kaplan–Meier plot for cumulative response on first interim positron–emission tomography/computed tomography in
Hodgkin and non-Hodgkin lymphomas against median baseline lesion size in the largest dimension. HL = Hodgkin
lymphoma, NHL = Non-Hodgkin lymphoma
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